Suzanne L. Topalian

96.6k total citations · 31 hit papers
215 papers, 49.2k citations indexed

About

Suzanne L. Topalian is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Suzanne L. Topalian has authored 215 papers receiving a total of 49.2k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Oncology, 120 papers in Immunology and 45 papers in Molecular Biology. Recurrent topics in Suzanne L. Topalian's work include Cancer Immunotherapy and Biomarkers (113 papers), Immunotherapy and Immune Responses (101 papers) and CAR-T cell therapy research (52 papers). Suzanne L. Topalian is often cited by papers focused on Cancer Immunotherapy and Biomarkers (113 papers), Immunotherapy and Immune Responses (101 papers) and CAR-T cell therapy research (52 papers). Suzanne L. Topalian collaborates with scholars based in United States, France and Netherlands. Suzanne L. Topalian's co-authors include Drew M. Pardoll, Steven A. Rosenberg, Charles G. Drake, Janis M. Taube, James Chih‐Hsin Yang, Douglas J. Schwartzentruber, Robert A. Anders, Richard M. Sherry, Claudia A. Seipp and Donald E. White and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Suzanne L. Topalian

212 papers receiving 48.2k citations

Hit Papers

Immune Checkpoint Blockad... 1988 2026 2000 2013 2015 2010 2002 2003 2016 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
    2015 3.1k citations Suzanne L. Topalian, Charles G. Drake et al. profile →
  2. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    2010 2.3k citations Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology profile →
  3. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
    2002 2.2k citations Mark E. Dudley, John R. Wunderlich et al. Science profile →
  4. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
    2003 2.1k citations James Chih‐Hsin Yang, Leah Haworth et al. profile →
  5. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
    2016 2.0k citations Suzanne L. Topalian, Janis M. Taube et al. profile →
  6. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
    2006 2.0k citations Richard A. Morgan, Mark E. Dudley et al. Science profile →
  7. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
    2014 1.9k citations Janis M. Taube, Alison Klein et al. Clinical Cancer Research profile →
  8. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
    1988 1.8k citations Steven A. Rosenberg, Diane Solomon et al. profile →
  9. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
    2012 1.7k citations Janis M. Taube, Robert A. Anders et al. profile →
  10. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
    1998 1.5k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. profile →
  11. Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
    2011 1.3k citations Suzanne L. Topalian, Drew M. Pardoll et al. profile →
  12. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
  13. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
    1998 1.1k citations Suzanne L. Topalian, Seth M. Steinberg et al. Journal of Clinical Oncology profile →
  14. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    2012 1.1k citations Suzanne L. Topalian, Charles G. Drake et al. profile →
  15. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
    2010 954 citations Richard E. Royal, Marybeth S. Hughes et al. Journal of Immunotherapy profile →
  16. Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction
    1990 898 citations Steven A. Rosenberg, Richard A. Morgan et al. profile →
  17. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
    1994 886 citations Suzanne L. Topalian, Steven A. Rosenberg et al. Proceedings of the National Academy of Sciences profile →
  18. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
    2017 874 citations Suzanne L. Topalian et al. Journal of Clinical Oncology profile →
  19. Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2
    1994 779 citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. profile →
  20. Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
    2005 771 citations Giao Q. Phan, Martha Quezado et al. Journal of Clinical Oncology profile →
  21. Neoadjuvant checkpoint blockade for cancer immunotherapy
    2020 664 citations Suzanne L. Topalian, Janis M. Taube et al. Science profile →
  22. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
    2006 646 citations Joseph Blansfield, Khoi Q. Tran et al. Journal of Clinical Oncology profile →
  23. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
    2013 602 citations Sofía Lyford-Pike, Shiwen Peng et al. Cancer Research profile →
  24. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
    2003 573 citations James Chih‐Hsin Yang, Richard M. Sherry et al. Journal of Clinical Oncology profile →
  25. The role of CD4+ T cell responses in antitumor immunity
    1998 569 citations Drew M. Pardoll, Suzanne L. Topalian profile →
  26. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma
    2002 565 citations Patrick Hwu, Nicholas P. Restifo et al. Journal of Clinical Oncology profile →
  27. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
    2007 537 citations James Chih‐Hsin Yang, Marybeth S. Hughes et al. Journal of Immunotherapy profile →
  28. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
    2019 409 citations Suzanne L. Topalian, Julie R. Brahmer et al. profile →
  29. Mechanisms regulating PD-L1 expression on tumor and immune cells
    2019 345 citations Shuming Chen, Theresa S. Pritchard et al. Journal for ImmunoTherapy of Cancer profile →
  30. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
    2019 299 citations Tim Meyer, Suzanne L. Topalian et al. Journal of Clinical Oncology profile →
  31. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
    2023 153 citations Suzanne L. Topalian, Patrick M. Forde et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suzanne L. Topalian United States 82 32.6k 27.0k 12.4k 7.7k 4.4k 215 49.2k
Lieping Chen United States 112 34.3k 1.1× 36.0k 1.3× 9.2k 0.7× 6.6k 0.8× 2.4k 0.6× 368 55.6k
Jedd D. Wolchok United States 119 45.3k 1.4× 29.7k 1.1× 16.2k 1.3× 11.0k 1.4× 2.8k 0.6× 568 65.0k
F. Stephen Hodi United States 101 34.2k 1.0× 16.7k 0.6× 10.4k 0.8× 9.8k 1.3× 1.7k 0.4× 517 44.0k
Gordon J. Freeman United States 141 38.6k 1.2× 54.1k 2.0× 14.7k 1.2× 8.3k 1.1× 4.1k 0.9× 419 82.7k
Antoni Ribas United States 110 39.7k 1.2× 22.6k 0.8× 27.4k 2.2× 7.5k 1.0× 2.9k 0.7× 551 61.0k
Wolf H. Fridman France 100 27.6k 0.8× 31.2k 1.2× 16.6k 1.3× 8.5k 1.1× 2.2k 0.5× 529 57.4k
John M. Kirkwood United States 104 31.3k 1.0× 18.8k 0.7× 17.9k 1.4× 4.4k 0.6× 2.0k 0.5× 687 46.4k
Elizabeth M. Jaffee United States 89 18.4k 0.6× 15.8k 0.6× 9.3k 0.7× 3.9k 0.5× 2.7k 0.6× 386 30.7k
Steven Μ. Albelda United States 96 13.2k 0.4× 13.6k 0.5× 10.6k 0.9× 5.2k 0.7× 4.1k 0.9× 315 35.5k
Dmitry I. Gabrilovich United States 97 25.8k 0.8× 41.6k 1.5× 15.6k 1.3× 4.3k 0.6× 1.6k 0.4× 266 57.3k

Countries citing papers authored by Suzanne L. Topalian

Since Specialization
Citations

This map shows the geographic impact of Suzanne L. Topalian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne L. Topalian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne L. Topalian more than expected).

Fields of papers citing papers by Suzanne L. Topalian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne L. Topalian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne L. Topalian. The network helps show where Suzanne L. Topalian may publish in the future.

Co-authorship network of co-authors of Suzanne L. Topalian

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne L. Topalian. A scholar is included among the top collaborators of Suzanne L. Topalian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne L. Topalian. Suzanne L. Topalian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeng, Zhen, Jiajia Zhang, Shuai Li, et al.. (2025). A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types. Nature Communications. 16(1). 1070–1070. 4 indexed citations
2.
Topalian, Suzanne L. & Drew M. Pardoll. (2025). Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care. Journal for ImmunoTherapy of Cancer. 13(1). e010833–e010833. 6 indexed citations
3.
Bhatia, Shailender, Suzanne L. Topalian, William H. Sharfman, et al.. (2025). Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. Journal of Clinical Oncology. 43(9). 1137–1147. 7 indexed citations
4.
Chen, Shuming, Tracee L. McMiller, Abha Soni, et al.. (2024). Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade. Journal of Translational Medicine. 22(1). 241–241. 6 indexed citations
5.
McMiller, Tracee L., Sepideh Besharati, Mark Yarchoan, et al.. (2024). Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy. Journal for ImmunoTherapy of Cancer. 12(11). e010201–e010201. 3 indexed citations
6.
Rosner, Samuel, Joshua E. Reuss, Marianna Zahurak, et al.. (2023). Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(4). 705–710. 44 indexed citations
7.
Deutsch, Julie S., Evan J. Lipson, Ludmila Danilova, et al.. (2023). Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Reports Medicine. 4(2). 100947–100947. 18 indexed citations
8.
Stein, Julie E., Evan J. Lipson, Tricia R. Cottrell, et al.. (2019). Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research. 26(3). 545–551. 92 indexed citations
9.
Miller, Natalie, Candice D. Church, Steven P. Fling, et al.. (2018). Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. Journal for ImmunoTherapy of Cancer. 6(1). 131–131. 27 indexed citations
10.
Ascierto, Maria Libera, Tracee L. McMiller, Alan E. Berger, et al.. (2016). The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research. 4(9). 726–733. 133 indexed citations
11.
Taube, Janis M., Geoffrey D. Young, Tracee L. McMiller, et al.. (2015). Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical Cancer Research. 21(17). 3969–3976. 196 indexed citations
12.
Rodić, Nemanja, Robert A. Anders, James R. Eshleman, et al.. (2014). PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research. 3(2). 110–115. 42 indexed citations
13.
Taube, Janis M., Alison Klein, Julie R. Brahmer, et al.. (2014). Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy. Clinical Cancer Research. 20(19). 5064–5074. 1873 indexed citations breakdown →
14.
Lyford-Pike, Sofía, Shiwen Peng, Geoffrey D. Young, et al.. (2013). Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research. 73(6). 1733–1741. 602 indexed citations breakdown →
15.
Blansfield, Joseph, Khoi Q. Tran, Andrew L. Feldman, et al.. (2006). Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. Journal of Clinical Oncology. 24(15). 2283–2289. 646 indexed citations breakdown →
16.
Morgan, Richard A., Mark E. Dudley, John R. Wunderlich, et al.. (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science. 314(5796). 126–129. 1961 indexed citations breakdown →
17.
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377. 1234 indexed citations breakdown →
18.
Phan, Giao Q., Christopher E. Touloukian, James C. Yang, et al.. (2003). Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens. Journal of Immunotherapy. 26(4). 349–356. 91 indexed citations
19.
Topalian, Suzanne L., Syuzo Kaneko, Monica I. Gonzales, et al.. (2001). Identification and Functional Characterization of Neo-Poly(A) Polymerase, an RNA Processing Enzyme Overexpressed in Human Tumors. Molecular and Cellular Biology. 21(16). 5614–5623. 116 indexed citations
20.
Schwartzentruber, Douglas J., Diane Solomon, Steven A. Rosenberg, & Suzanne L. Topalian. (1992). Characterization of Lymphocytes Infiltrating Human Breast Cancer, Specific Immune Reactivity Detected by Measuring Cytokine Secretion. Journal of Immunotherapy. 12(1). 1–1. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lieping Chen Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by F. Stephen Hodi Breakdown of academic impact, for papers by Gordon J. Freeman Breakdown of academic impact, for papers by Antoni Ribas Breakdown of academic impact, for papers by Wolf H. Fridman Breakdown of academic impact, for papers by John M. Kirkwood Breakdown of academic impact, for papers by Elizabeth M. Jaffee Breakdown of academic impact, for papers by Steven Μ. Albelda Breakdown of academic impact, for papers by Dmitry I. Gabrilovich
Rankless by CCL
2026